Experimental cancer drug trial halted early

NCT ID NCT06540066

Terminated Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new antibody drug (BGB-B3227) alone or with another drug (tislelizumab) in 35 people with advanced solid tumors. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER ADVANCED SOLID TUMOR METASTATIC CANCER METASTATIC SOLID TUMOR

Contacts and locations

Locations

Affiliated Zhongshan Hospital of Fudan University

Shanghai, Shanghai Municipality, 200032, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China
Fondazione Irccs Istituto Nazionale Dei Tumori

Milan, 20133, Italy
Fondazione Policlinico Universitario Agostino Gemelli

Roma, 00168, Italy
Hackensack University Medical Center

Hackensack, New Jersey, 07601-1915, United States
Istituto Clinico Humanitas

Rozzano, 20089, Italy
Istituto Europeo Di Oncologia

Milan, 20141, Italy
Md Anderson Cancer Center

Houston, Texas, 77030-3907, United States
Next Oncology

Austin, Texas, 78758, United States
Usc Norris Comprehensive Cancer Center (Nccc)

Los Angeles, California, 90089-1019, United States
Washington University in St Louis

St Louis, Missouri, 63110-1010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.